Catasys, Inc. Executive Informational Overview Introduction
1. .
o Provider of big dataābased analytics and predictive modelingā
driven health management services for health plans. These
services aim to improve member health while simultaneously
lowering insurer costs for underserved populations.
o Catasysā analytics identify which individuals on an insurance plan
are āhigh utilizersā with impactable costs due to having a
substance dependency or anxiety disorder exacerbating
coexisting medical conditions.
- proprietary direct outreach capability to enroll target health
plan members in the OnTrakā¢ patient-centric treatment program
o OnTrakā¢ has shown a 50%+ reduction in total costs for health
insurersā enrolled membersāstemming from decreases in
hospital stays, ambulance usage, and ER visits.
Crystal Research Associates Presents:
New Independent Equity Research
A 56-page Executive Informational OverviewĀ® (EIO) by Crystal Research Associates is
available on Catasys, Inc. (CATS-OTC) at www.crystalra.com.
2. .
ā¢ Crystal clear, comprehensive report on a company in a manner that is
easily understood by the Wall Street financial community
ā¢ Product/technology/service offerings, market size(s), key intellectual
property, leadership, growth strategy, competition, risks, financial
statements, key events, and other fundamental information are
detailed
ā¢ Free of investment ratings, target prices, and forward-looking financial
models
ā¢ Complete risks and disclosures
ā¢ Written exclusively by experienced, award-winning analysts
What is an EIO?
3. .
Overview of Catasys, Inc. (CATS-OTC)
ā¢ Catasysā proprietary data analytics enables it to identify high-cost, substance-dependent members within
health insurance plans who have the potential to have reduced costs through effective treatment of their
behavioral health conditions. The Company reaches out to these specific members and is typically able to
persuade an average of 20% of a planās eligible substance-dependent individuals to enroll in the OnTrakā¢
treatment program.
ā¢ Catasys views substance dependence as a chronic disease, where successful patient outcomes require
provider coordination, a whole-person-health treatment philosophy, member skill building, and long-term
reinforcement. OnTrakā¢ uses standardized, evidence-based medical and psychosocial interventions in a 52-
week outpatient program that enables consistent quality of care supported by membersā own Care Coaches.
ā¢ Enrollment in OnTrakā¢ increased 102% in Q2 2015 versus Q1 2015, and Catasysā Q2 2015 revenue was up
51% year-over-year. OnTrakā¢ is currently available through insurance providers in 10 states, including
Aetna/Coventry, Humana, Centene, Fallon Health, Health Alliance Medical Plans, and Reliant Medical Group.
ā¢ Catasys provides health plans with outcomes reporting as it relates to clinical and financial metrics to
demonstrate and confirm the value of its programāwith data showing an average gross cost reduction of
>50% versus the prior 12 months of enrollment. Furthermore, roughly 80% of members who have remained
eligible have stayed in the program to date. This data is key to increasing adoption of OnTrakā¢.
ā¢ A normal covered life averagely costs a health plan $3,250/year while a high-utilizer, substance-dependent
life costs $27,500. If insurers pay Catasys, for example, $8,500 per member who enrolls in OnTrakā¢, and
OnTrakā¢ generates a 50% cost savings, there is a potential savings to insurers in the first year of ~$5,250
per enrolled member. The savings is expected to continue after the first year.
4. .
Experienced Leadership
ā¢ Catasys is run by senior management that collectively has over 50 years of substance dependence
treatment experience and over 100 years of healthcare experience, having developed an expertise
in engaging, treating, and empowering members with coexisting medical and behavioral conditions
to modify their behavior.
ā¢ Terren S. Peizer, director, chairman of the board, and CEO, has personally invested ~$16 million into
Catasysāsomewhat uncharacteristic for a microcap company.
Terren S. Peizer, Chairman, Founder & CEO
ļ§ Background in venture capital, investing, M&A, corporate
finance
ļ§ Senior executive positions with Goldman Sachs, First
Boston, and Drexel Burnham Lambert
ļ§ Chairman of Crede Capital Group, LLC
Richard A. Anderson, President & COO
ļ§ Over 15 years of healthcare experience and background
in management, finance, and M&A
ļ§ Previously director and founding member of
PriceWaterhouseCoopersā Los Angeles office transaction
support group
Susan Etzel, CPA & CFO
ļ§ Over 15 years in both public and private company finance
ļ§ Senior auditor at Arthur Andersen LLP
Omar Manejwala, M.D., SVP & CMO
ļ§ Distinguished Fellow of the American Psychiatric Association
and Diplomate of the American Board of Addiction Medicine
ļ§ Previous medical director at Hazelden, associate medical
director at the Farley Center, and executive chief resident in
psychiatry at Duke University Medical Center
W. Gregory McLane, SVP, Sales & Marketing
ļ§ Led marketing activities for Magellan Health Services and
founded health benefits company, Optimized Benefits, Inc.
ļ§ Led strategy and product development for CIGNA and ran
consumer products businesses for Procter & Gamble,
Campbell Soup, and Nabisco
Barbara āBeā Stark, SVP, New Business Development
ļ§ Over 30 years of healthcare sales experience, including at
Coram, Novartis, Alere, Apria Healthcare, and more
ļ§ Previously SVP of sales at Univita Health
5. .
ļ§ Seeking to transform the entire health management services system, the OnTrakā¢ program has
shown to improve member health while reducing inpatient stays, emergency room utilization, and
insurersā total healthcare costs for enrolled members by more than 50%.
ļ§ Importantly, Catasysā system is set up in a novel manner for the behavioral healthcare industry, which
has historically struggled with providing adequate care and favorable economics due to a difficulty of
identifying and treating patients who have mental, behavioral, and substance use disorders.
ļ¼ Healthcare insurers/payers: Cost savings
ļ¼ Patients:
- Financially: For most members, OnTrakā¢ treatment is 100% covered under their health plan
(unusual for the industry)
- Medically: The treatment components of OnTrakā¢ as well as by encouraging better treatment
outcomes since patients do not have to avoid treatment or leave the program early due to
cost
ļ¼ Catasys: Revenue generated from health plans enrolling members
Potentially Transformative Strategies for
Behavioral Healthcare
6. .
Costs of Undiagnosed and Untreated Behavioral
Health Issues
Healthcare Overall
Tobacco $130Ā billion $295Ā billion
Alcohol $25Ā billion $224Ā billion
IllicitĀ Drugs $11Ā billion $193Ā billion
Source:Ā theĀ NationalĀ InstituteĀ onĀ DrugĀ Abuse,Ā JanuaryĀ 2015.
COSTSĀ OFĀ SUBSTANCEĀ ABUSE
OnTrakā¢ may help fill the gap that exists as underserved populations with behavioral health
conditions do not seek treatment.
ļ® Over the past several decades, there has been a change in how the U.S. views mental health issues.
Today, a conversation about a tragic shooting has transitioned from being an āNRA issueā to a āmental
health issue,ā with these topics being picked up by industry, media, and politicians alike. With near-daily
news reports of teenage or young adult suicides, attacks on family, military, schools, movie theaters, and
so on by undiagnosed and untreated individuals, and a rise in accidental drug overdoses from both illicit
and prescription products, conversations have begun to focus on increasing fairness in health insurance
for behavioral and mental health conditions while reducing the stigma, costs, and hopelessness of seeking
treatment for those who are suffering from a mental or substance disorder.
ļ§ Substance abuse costs the U.S. over $700
billion annually due to crime, lost work
productivity, and healthcare.
o As of 2013, approximately 22.7 million U.S.
residents needed treatment for a problem
related to drugs or alcohol, though only 2.5
million people had received treatment at a
specialty facility.
7. .
Need to Address Comorbidities
In any given 30-day period, 10% of the U.S. population is on five or more prescription drugs, many common
combinations of which are extremely habit-forming and have a high rate of abuse by patients (Source: CDC).
As ofĀ 2012:
41,502Ā drugĀ overdoseĀ deaths
Nearly80%Ā ofĀ whichĀ wereĀ unintentional
OpioidĀ
analgesicsĀ
(prescriptionĀ
painkillers)
72%
BenzodiazepinesĀ
(prescriptionĀ
antiāanxiety)
30%OtherĀ
drugs
47%
Pharmaceuticals
53%
Causes ofĀ FatalĀ OverdoseĀ (2012)
Causes ofĀ FatalĀ OverdoseĀ fromĀ Prescription
PharmaceuticalsĀ OnlyĀ (2012)*
259Ā million:Ā
NumberĀ ofĀ prescriptionsĀ forĀ painkillersĀ
writtenbyĀ healthcareĀ providersĀ inĀ 2012
* SomeĀ deathsĀ involvedĀ moreĀ
thanĀ oneĀ typeĀ ofĀ drug,Ā asĀ
peopleĀ whoĀ diedĀ ofĀ drugĀ
overdosesĀ oftenĀ hadĀ aĀ
combinationĀ ofĀ
benzodiazepinesĀ andĀ opioidĀ
analgesicsĀ inĀ theirĀ bodies.
ā¢ There is a need for substance abuse programs to include
physicians trained to fully assess not only the substance
dependence but also any other comorbid conditions and
concerns that may inhibit better health.
ā¢ Catasys has found that many of the high-utilizer
individuals identified by its program tend to have
chronic and interrelated, comorbid conditions that also
need to be managed.
9. .
Catasysā program is helping make
substance dependency treatment the
same as any medical, pharmacological, or
pharmaceutical treatment, where Catasys
IS the treatment.
10. .
The OnTrakā¢ Program
ā OngoingĀ outreachĀ andĀ engagementĀ ā IdentifiesĀ membersĀ whereĀ theĀ programĀ canĀ haveĀ anĀ impact
ā EvidenceābasedĀ treatmentĀ protocolsĀ ā EngagesĀ theseĀ members
ā IntegratedĀ medicalĀ andĀ psychosocialĀ treatment ā Enrolls/refersĀ theseĀ members
ā DevelopmentĀ ofĀ selectĀ providerĀ networksĀ ā HasĀ aĀ providerĀ network
ā ProviderĀ trainingĀ andĀ ongoingĀ evaluationsĀ ā ProvidesĀ forĀ outpatientĀ medicalĀ treatment
ā MemberĀ electronicĀ healthĀ recordĀ Ā ā ProvidesĀ forĀ outpatientĀ psychosocialĀ treatment
ā CareĀ coachĀ supportĀ ā ProvidesĀ forĀ careĀ coaching
ā ā MonitorsĀ andĀ reports
ā
ā Highāintensity,Ā 52āweekĀ program
KEYĀ FEATURESĀ OFĀ ONTRAKā¢
PredictiveĀ modelingĀ andĀ analyticsĀ (proactiveĀ versusĀ
reactiveĀ identificationĀ andĀ engagement)
ONTRAKā¢Ā APPROACH
HasĀ aĀ webābasedĀ clinicalĀ informationĀ platformĀ calledĀ
eOnTrakā¢
ā¢ Developed by specialists in addiction
ā¢ Specially trained network of providers who employ medical/psychosocial treatment modalities, such as the
OnTrakā¢ Relapse Prevention Program, to assist in developing coping skills and a recovery support network
ā¢ Catasysā Care Coaches work directly with members by proactively providing support to enhance motivation,
minimize lapses, and enable lifestyle modifications.
ā¢ Managed through eOnTrakā¢, a web-based clinical information platform that allows each member of the
treatment team (providers/Care Coaches/patients) to be better educated regarding treatment
11. .
Current Clients
ļ§ OnTrakā¢ is currently available in 10 states, including through the insurance providers shown below.
ļ§ Collectively, this entails approximately 2.3 million Commercially Equivalent Lives (CELs). Catasysā
pipeline includes 10 million additional CELs, with 4 million in advanced discussions. CELs are a
metric of growth potential, as increasing CELs may represent increasing future enrollment.
12. .
Catasysā Growth Strategies
ā¢ Demonstrating and validating the potential for better clinical outcomes and lower costs
using the Companyās OnTrakā¢ program with key managed care and other third-party payers
ā¢ Educating third-party payers about the excessively high costs related to their substance-
dependent members
ā¢ Providing OnTrakā¢ to third-party payers for reimbursement on a case rate, fee-for-service, or
monthly fee basis
ā¢ Generating outcomes data from OnTrakā¢ that demonstrates cost reductions and using this
data to increase adoption. The Company believes that OnTrakā¢ could help fill the gap where
there is an absence of programs that proactively engage the right individuals in smaller
populations with excessively higher costs driven by behavioral health conditions.
14. .
Crystal Research Associates, LLC (www.crystalra.com) is an independent research firm that
has provided institutional-quality research on small- and mid-cap companies for the past
decade. We are led by veteran Wall Street sell-side analyst Jeffrey Kraws, who is well known by
the international financial media for his years of work on Wall Street and for providing
consistent award-winning analyses and developing long-term relationships on both the buy-
side and sell-side. He has been consistently ranked among the Top Ten Analysts for
pharmaceutical stock performance in the world for almost two decades as well as ranked as
the Number One Stock Picker in the world for pharmaceuticals by Starmine and for estimates
from Zacks. Additionally, Mr. Kraws has been 5-Star ranked for top biotechnology stock
performance by Starmine.
About Us
Corporate Headquarters:
880 Third Avenue, 6th Floor
New York, NY 10022
Office: (212) 851-6685
Fax: (609) 395-9339Jeffrey J. Kraws,
Chief Executive Officer
Karen B. Goldfarb
President & COO